Prof. MUDr. Petr Arenberger, DrSc, MBA, FCMA ****************************************************************************************** * ******************************************************************************************
Department of Dermatovenereology, Third Faculty of Medicine, Charles University and Univer Kralovske Vinohrady https://www.lf3.cuni.cz/3LF-998.html [ URL "https://www.lf3.cuni.cz/3LF-998.html"] Topic title Epidemiology of mycosis fungoides patients *========================================================================================= * Description of scientific activity *========================================================================================= Petr Arenberger is a Professor and Chairman at the Department of Dermatovenereology, Third Medicine, Charles University, and University Hospital Kralovske Vinohrady, Prague. He completed his medical degree at the Charles University, Prague, in 1984, and started hi the 1st Dept. of Dermatovenereology, Faculty Hospital, Prague 2. In 1987 he spent 1 year a Allergy, Faculty Hospital, Prague 10. Since 1988 he has been working at the Dept. of Derma Charles University, Third Faculty of Medicine, with 3 years at the Ludwig Maximilian Unive Germany, and Stanford University, Palo Alto, California, USA. Since 2001 he is a Chair at the Dept. of Dermatovenereology, Charles University, Third Med University Hospital Kralovske Vinohrady, Prague, with broad interest in dermatology. Accor he authored and co-authored 146 publications in peer-reviewed journals, WOS is registering with the H-index of 23. His scientific interests include psoriasis, atopic eczema, melanom epidermal and hematological malignant skin tumors, targeted therapy of skin cancer, pathop vulgaris, hidradenitis suppurativa, chronic wounds and bacterial and viral skin infections time he is involved in the dermatosurgery and and aesthetic dermatology. Clinical trials – since 1995, more than 80 clinical trials as a Principle Investigator in eczema, leg ulcers (chronic wounds), melanoma, basal cell carcinoma, Merkel cell carcinoma carcinoma, chronic urticaria, herpes zoster, herpes simplex etc. Petr became a honorary member in 6 dermatological societies (German, Austrian, North Ameri Hungarian and Czech). He is serving as president of the Czech Dermatovenereology Society a European Board of Dermatovenereology of the European Union of Medical Specialists, as a vi the Czech Medical Association and as a board member of the Society for Corrective and Aest and of the Scientific Board of the Czech Medical Chamber. He became 2 awards - Silver Meda Parliament – Senate for the life-long contribution to dermatovenereology 2017 and from the Best Physician of the year 2017. *========================================================================================= * Selected publications *========================================================================================= Gollnick H.P.M., Arenberger P., Czarnecka-Operacz M.: Training requirements and recommenda specialty of dermatology and venereology European Standards of Postgraduate Medical Specia Eur Acad Dermatol Venereol. 2019 Jul;33 Suppl 4(Suppl Suppl 4):3-25. Arenberger P, Fialova A, Gkalpakiotis S, Pavlikova A, Puzanov I, Arenbergerova M. Melanoma biomarkers for ipilimumab response. J Eur Acad Dermatol Venereol. 2017 Feb;31(2):252-259. Mandala M, Larkin J, Ascierto PA, Del Vecchio M, Gogas H, Cowey CL, Arance A, Dalle S, Sch Chiarion-Sileni V, Marquez-Rodas I, Butler MO, Di Giacomo AM, Lutzky J, De La Cruz-Merino Arenberger P, Hill A, Fecher L, Millward M, Khushalani NI, de Pril V, Lobo M, Weber J. Adj for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-f Immunother Cancer. 2021 Aug;9(8):e003188. *========================================================================================= * Selected or ongoing grants/clinical studies *========================================================================================= Arenberger P., Pavelka K., Lukáš M.: Appropriate Immunization among Patients with Immune-M Inflammatory Diseases (IMIDs) – quality improvement and data access project. Pfizer 2021 # A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy With Nivolumab Versus Complete Resection of Stage IIB/C Melanoma A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab Versus Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects Who Are at High Risk f *========================================================================================= * PhD Students *========================================================================================= Number of PhD students currently studying: 4 Number of defended students with year of defence: 2 PhD. (2010 and 2020)